Online inquiry

IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3413MR)

This product GTTS-WQ3413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ALB gene. The antibody can be applied in Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213
UniProt ID P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3413MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4514MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ6226MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ9297MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ7193MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ10260MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ14215MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ15332MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ3743MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW